Last reviewed · How we verify
Seasonal Influenza DNA vaccine
Seasonal Influenza DNA vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 1 development. Also known as: VRC-FLUDNA063-00-VP, HA DNA Vaccine, Seasonal influenza trivalent DNA vaccine.
At a glance
| Generic name | Seasonal Influenza DNA vaccine |
|---|---|
| Also known as | VRC-FLUDNA063-00-VP, HA DNA Vaccine, Seasonal influenza trivalent DNA vaccine |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years (PHASE1)
- Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents (PHASE1)
- VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat... (PHASE1)
- VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years (PHASE1)
- Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone (PHASE1)
- DNA-based Influenza Vaccine in the Elderly (PHASE1)
- A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seasonal Influenza DNA vaccine CI brief — competitive landscape report
- Seasonal Influenza DNA vaccine updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Seasonal Influenza DNA vaccine
What is Seasonal Influenza DNA vaccine?
Seasonal Influenza DNA vaccine is a Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID).
Who makes Seasonal Influenza DNA vaccine?
Seasonal Influenza DNA vaccine is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).
Is Seasonal Influenza DNA vaccine also known as anything else?
Seasonal Influenza DNA vaccine is also known as VRC-FLUDNA063-00-VP, HA DNA Vaccine, Seasonal influenza trivalent DNA vaccine.
What development phase is Seasonal Influenza DNA vaccine in?
Seasonal Influenza DNA vaccine is in Phase 1.
Related
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Also known as: VRC-FLUDNA063-00-VP, HA DNA Vaccine, Seasonal influenza trivalent DNA vaccine
- Compare: Seasonal Influenza DNA vaccine vs similar drugs
- Pricing: Seasonal Influenza DNA vaccine cost, discount & access